CELC FINANCIAL STATEMENTS

Celcuity LLC — balance sheet, income statement and cash flow trends

CELCCelcuity LLC

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue154 K $+26.9%

Gross Profit-128 K $—

Operating Income-186.6 M $—

EBITDA-172.7 M $—

Net Income-192.9 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CELC	26.9%	-83.1%	-112,116.2%	-125,250.6%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CELC	26.9%	-83.1%	-112,116.2%	-125,250.6%
ERAS	-100.0%	—	—	—
LGND	51.2%	98.6%	81.0%	55.9%
ACLX	-79.4%	-64.8%	-888.3%	-1,027.3%
TVTX	96.0%	94.0%	7.2%	-4.0%
PTCT	-53.3%	77.8%	-14.5%	-22.6%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity53.5 M $13%
Current Liabilities33.2 M $8%
Long-term Liabilities323.4 M $79%

Key Figures

YoY change

Total Assets410.2 M $+88.0%

Total Liabilities356.6 M $+171.3%

Total Equity53.5 M $-38.2%

Cash & ST Investments145.2 M $-29.4%

Total Debt195.6 M $+98.1%

Net Debt50.4 M $-38.7%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CELC	12.31	365.4%	-0.29	13.0%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CELC	12.31	365.4%	-0.29	13.0%
ERAS	9.52	11.7%	0.73	85.3%
LGND	21.28	45.3%	-1.47	65.1%
ACLX	4.44	23.9%	1.79	66.6%
TVTX	3.13	331.9%	1.63	17.8%
PTCT	2.44	-218.9%	12.52	-6.3%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-172.5 M $—

Capital Expenditures438 K $+99.2%

Free Cash Flow-172.9 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CELC	-112,007.8%	-112,292.2%	284.4%	89.4%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CELC	-112,007.8%	-112,292.2%	284.4%	89.4%
ERAS	—	—	—	33.0%
LGND	45.0%	44.8%	0.2%	80.4%
ACLX	-943.5%	-953.9%	10.4%	91.8%
TVTX	7.4%	-0.3%	7.7%	-184.9%
PTCT	-26.4%	-31.9%	5.6%	116.7%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CELC

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.